Chemoimmunotherapy with NK cells for high-risk neuroblastoma
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of neuroblastoma or ganglioneuroblastoma that is considered high-risk.
- You must be between 18 months and 18 years old.
- Your cancer did not respond well to initial therapy (refractory) or has come back after a period of improvement (relapsed).
- You need to be in generally good health, with enough heart, liver, kidney, lung, and blood clotting function.
- You cannot have cancer that has spread to your brain or spinal cord membranes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
Hear when a new Neuroblastoma (NB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.